Gilead/Achillion Advance Back-Up Anti-HCV Molecule After Toxicity Problems With Lead Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies plan IND filing for their next novel NS4A antagonist in the first or second quarter of 2008.
You may also be interested in...
Vertex Hopes To PROVE Telaprevir’s Promise With Final Installment Of Phase II Program
Company plans to begin Phase III in the second half of 2007; further protocol discussions with FDA are planned for mid-2007.
AstraZeneca Hits Anti-Infective Target With Arrow Acquisition
Acquisition of U.K. biotech reflects AstraZeneca's core therapeutic focus in infection, the company says.
Novartis/HGS’ Albuferon May Offer Dosing Advantages Over Roche’s Pegasys
Phase III program for the chronic hepatitis C treatment includes two non-inferiority trials comparing once-weekly Pegasys to bi-weekly Albuferon.